Iloprost Suppresses Connective Tissue Growth Factor Production in Fibroblasts and in the Skin of Scleroderma Patients

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2001 Jul 18

PMID 11457877

Citations 55

Authors

R Stratton

X Shiwen

G Martini

A Holmes

A Leask

T Haberberger

G R Martin

C M Black

D Abraham

Affiliations

Soon will be listed here.

Abstract

Patients with scleroderma receiving Iloprost as a treatment for severe Raynaud's phenomenon report a reduction in skin tightness, suggesting that this drug inhibits skin fibrosis. Connective tissue growth factor (CTGF), a recently described profibrotic cytokine, acts downstream and in concert with TGF-beta to stimulate the fibrotic process and is involved in the fibrosis seen in scleroderma. Here we show that Iloprost, acting by elevation of cAMP, blocks the induction of CTGF and the increase in collagen synthesis in fibroblasts exposed to TGF-beta. The potency of Iloprost with respect to suppression of CTGF far exceeds that of other prostanoid receptor agonists, suggesting that its effect is mediated by the prostacyclin receptor IP. By sampling dermal interstitial fluid using a suction blister device, we show that CTGF levels are greatly elevated in the dermis of scleroderma patients compared with healthy controls and that Iloprost infusion causes a marked decrease in dermal CTGF levels. These studies suggest that Iloprost could be reducing the level of a key profibrotic cytokine in scleroderma patients and that endogenous production of eicosanoids may limit the fibrotic response to TGF-beta.

Citing Articles

Morphea: The 2023 update.

Papara C, De Luca D, Bieber K, Vorobyev A, Ludwig R Front Med (Lausanne). 2023; 10:1108623.

PMID: 36860340 PMC: 9969991. DOI: 10.3389/fmed.2023.1108623.

Multifunctional regulatory protein connective tissue growth factor (CTGF): A potential therapeutic target for diverse diseases.

Fu M, Peng D, Lan T, Wei Y, Wei X Acta Pharm Sin B. 2022; 12(4):1740-1760.

PMID: 35847511 PMC: 9279711. DOI: 10.1016/j.apsb.2022.01.007.

Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need.

Herrick A, Assassi S, Denton C Nat Rev Rheumatol. 2022; 18(5):276-285.

PMID: 35292731 PMC: 8922394. DOI: 10.1038/s41584-022-00765-9.

Iloprost Attenuates Oxidative Stress-Dependent Activation of Collagen Synthesis Induced by Sera from Scleroderma Patients in Human Pulmonary Microvascular Endothelial Cells.

Giordo R, Thuan D, Posadino A, Cossu A, Zinellu A, Erre G Molecules. 2021; 26(16).

PMID: 34443317 PMC: 8399120. DOI: 10.3390/molecules26164729.

Upcoming treatments for morphea.

Wenzel D, Haddadi N, Afshari K, Richmond J, Rashighi M Immun Inflamm Dis. 2021; 9(4):1101-1145.

PMID: 34272836 PMC: 8589364. DOI: 10.1002/iid3.475.

References

Korn J, Halushka P, LeRoy E . Mononuclear cell modulation of connective tissue function: suppression of fibroblast growth by stimulation of endogenous prostaglandin production. J Clin Invest. 1980; 65(2):543-54. PMC: 371393. DOI: 10.1172/JCI109698. View

Vermeer B, Reman F, van Gent C . The determination of lipids and proteins in suction blister fluid. J Invest Dermatol. 1979; 73(4):303-5. DOI: 10.1111/1523-1747.ep12531833. View

Rossing N, Worm A . Interstitial fluid: exchange of macromolecules between plasma and skin interstitium. Clin Physiol. 1981; 1(3):275-84. DOI: 10.1111/j.1475-097x.1981.tb00896.x. View

Goldstein R, Polgar P . The effect and interaction of bradykinin and prostaglandins on protein and collagen production by lung fibroblasts. J Biol Chem. 1982; 257(15):8630-3. View

Town M, Schillinger E . Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors. Prostaglandins. 1983; 25(1):13-28. DOI: 10.1016/0090-6980(83)90131-4. View

Korn J . Fibroblast prostaglandin E2 synthesis. Persistence of an abnormal phenotype after short-term exposure to mononuclear cell products. J Clin Invest. 1983; 71(5):1240-6. PMC: 436984. DOI: 10.1172/jci110873. View

Lundberg C, Lebel L, Gerdin B . Inflammatory reaction in an experimental model of open wounds in the rat. The role of polymorphonuclear leukocytes. Lab Invest. 1984; 50(6):726-32. View

Krause W, Krais T . Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol. 1986; 30(1):61-8. DOI: 10.1007/BF00614197. View

Liel N, Mais D, Halushka P . Binding of a thromboxane A2/prostaglandin H2 agonist [3H]U46619 to washed human platelets. Prostaglandins. 1987; 33(6):789-97. DOI: 10.1016/0090-6980(87)90107-9. View

10.

McHugh N, Csuka M, Watson H, Belcher G, Amadi A, Ring E . Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis. 1988; 47(1):43-7. PMC: 1003442. DOI: 10.1136/ard.47.1.43. View

11.

Shindo N, Saito T, Murayama K . Rapid quantification of 11 prostanoids by combined capillary column gas chromatography and negative ion chemical ionization mass spectrometry: application to prostanoids released from normal human embryonic lung fibroblasts WI38 in a culture medium. Biomed Environ Mass Spectrom. 1988; 15(1):25-32. DOI: 10.1002/bms.1200150105. View

12.

LeRoy E, Black C, FLEISCHMAJER R, Jablonska S, Krieg T, Medsger Jr T . Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15(2):202-5. View

13.

Ashby B . Cyclic AMP turnover in response to prostaglandins in intact platelets: evidence for separate stimulatory and inhibitory prostaglandin receptors. Second Messengers Phosphoproteins. 1988; 12(1):45-57. View

14.

LeRoy E, Smith E, Kahaleh M, Trojanowska M, Silver R . A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor beta the answer?. Arthritis Rheum. 1989; 32(7):817-25. View

15.

Bunce K, Clayton N, Coleman R, Collington E, Finch H, Humphray J . GR63799X--a novel prostanoid with selectivity for EP3 receptors. Adv Prostaglandin Thromboxane Leukot Res. 1991; 21A:379-82. View

16.

Bradham D, Igarashi A, Potter R, Grotendorst G . Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol. 1991; 114(6):1285-94. PMC: 2289134. DOI: 10.1083/jcb.114.6.1285. View

17.

Lawrence R, Jones R, Wilson N . Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum. Br J Pharmacol. 1992; 105(2):271-8. PMC: 1908640. DOI: 10.1111/j.1476-5381.1992.tb14245.x. View

18.

Adie E, Mullaney I, McKenzie F, Milligan G . Concurrent down-regulation of IP prostanoid receptors and the alpha-subunit of the stimulatory guanine-nucleotide-binding protein (Gs) during prolonged exposure of neuroblastoma x glioma cells to prostanoid agonists. Quantification and functional.... Biochem J. 1992; 285 ( Pt 2):529-36. PMC: 1132820. DOI: 10.1042/bj2850529. View

19.

Igarashi A, Okochi H, Bradham D, Grotendorst G . Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell. 1993; 4(6):637-45. PMC: 300970. DOI: 10.1091/mbc.4.6.637. View

20.

Abramovitz M, Boie Y, Nguyen T, Rushmore T, Bayne M, Metters K . Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem. 1994; 269(4):2632-6. View